{{Rsnum
|rsid=2470152
|Gene=CYP19A1
|Chromosome=15
|position=51302775
|Orientation=minus
|GMAF=0.4876
|Gene_s=CYP19A1,LOC100996299
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 31.0 | 47.8 | 21.2
| HCB | 27.0 | 49.6 | 23.4
| JPT | 31.0 | 41.6 | 27.4
| YRI | 19.0 | 44.9 | 36.1
| ASW | 17.5 | 54.4 | 28.1
| CHB | 27.0 | 49.6 | 23.4
| CHD | 27.5 | 45.9 | 26.6
| GIH | 36.6 | 41.6 | 21.8
| LWK | 27.3 | 44.5 | 28.2
| MEX | 13.8 | 60.3 | 25.9
| MKK | 24.4 | 45.5 | 30.1
| TSI | 17.6 | 44.1 | 38.2
| HapMapRevision=28
}}{{PMID|19116238|OA=1
}} [[rs2470152]] is clearly associated with serum E2 and E1 levels in men, influencing risk of many conditions including [[prostate cancer]], [[breast cancer]] and [[osteoporosis]]

{{PMID Auto
|PMID=19818337
|Title=Association of genetic variations in aromatase gene with serum estrogen and estrogen/testosterone ratio in Chinese elderly men
}}

{{PMID Auto
|PMID=21972004
|Title=SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese             polycystic ovary syndrome patients
}}

{{PMID Auto
|PMID=22160249
|Title=Association of CYP19 Gene Polymorphism with Vertebral Fractures in Japanese Postmenopausal Women.
}}

{{PMID Auto
|PMID=23540392
|Title=Impact of aromatase genetic variation on hormone levels and global outcome after severe TBI.
}}

{{PMID Auto
|PMID=24803183
|Title=Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}